Drug combination delivered by nanoparticles may help in melanoma treatment
The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. With the drug, the cells have difficulty overcoming the effect of having more than one active ingredient. (Source: World Pharma News)
Source: World Pharma News - March 15, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Celecoxib: Cardiovascular Risk No Worse Than That of Nonselective NSAIDs
NEW ORLEANS — The cardiovascular safety profile of the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, a selective inhibitor of COX-2, is no worse than those of the nonselective NSAIDs naproxen and ibuprofen, according to a trial reported at the American Heart Association scientific sessions. (Source: Caring for the Ages)
Source: Caring for the Ages - January 31, 2017 Category: Health Management Authors: Susan London Source Type: news
Biomarkers Identified for Celecoxib Chemoprevention in CRC Biomarkers Identified for Celecoxib Chemoprevention in CRC
Potential biomarkers have been identified whichthat may be able to predict response to celecoxib when used as chemoprevention for colorectal cancer (CRC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Study Explores Safety of Celecoxib in Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - January 25, 2017 Category: Orthopaedics Tags: CME Article Source Type: news
Combined Biomarker Expression May Be Significant Driver of Tumorogenisis in Colorectum
Using immunohistochemistry to measure the expression of certain target enzymes —cox-2 and 15-prostaglandin dehydrogenase (15-PGDH)—in premalignant colorectal adenomas, researchers were able to get significant predictive and prognostic information in patients treated with the cox-2 inhibitor celecoxib for prevention of colorectal adenomas. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Colorectal Cancer News Source Type: news
AHA: Study Finds Celebrex Safe for Heart
Results of the PRECISION study are embraced by some and soundly criticized by others. What would you tell your osteoarthritis patients? (Source: ConsultantLive)
Source: ConsultantLive - December 2, 2016 Category: Internal Medicine Authors: Peggy Peck Tags: Cardiovascular Diseases Source Type: news
With No Increase in Heart Risk, Will You Prescribe Celebrex?
(MedPage Today) -- The cardiovascular risk cloud has been lifted -- will it make a difference? (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 28, 2016 Category: American Health Source Type: news
Morning Rounds: Celebrex, statins, and more
CBS News chief medical correspondent Dr. Jon LaPook looks at a new study that says the Celebrex arthritis drug does not pose a greater heart risk than rival drugs. Also, he is joined by CBS News contributor Dr. Tara Narula on "CBS This Morning: Saturday" to discuss recommendations for the use of the statin drugs to lower the risk of heart disease, and more. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 19, 2016 Category: Consumer Health News Source Type: news
Doctor on new Celebrex study: "Everybody was wrong – including me"
Researchers spent a decade studying the arthritis drug Celebrex to see if it causes heart problems, and now the surprising results are in (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news
PRECISION Results Open The Door For OTC Celebrex
They are highly motivated and will know quickly if OTC Celebrex is working for them or not. This is an ideal situation for an OTC drug. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 15, 2016 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE Source Type: news
Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: Study
Title: Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: StudyCategory: Health NewsCreated: 11/14/2016 12:00:00 AMLast Editorial Review: 11/15/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - November 15, 2016 Category: Cardiology Source Type: news
Celebrex study shows less risk to heart health than expected
Researchers spend a decade studying Celebrex, an arthritis drug, to see if it causes heart problems. A similar drug was removed from the market in 2004, as it increased the risk of heart attack and stroke. Dr. Jon LaPook reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news
Doctor on new Celebrex study: "Everybody was wrong -- including me"
Researchers spent a decade studying the arthritis drug Celebrex to see if it causes heart problems, and now the surprising results are in (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news
Bad News for Naproxen in RA
(MedPage Today) -- PRECISION study gives boost to Celebrex for RA (but not OA) patients (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 14, 2016 Category: Geriatrics Source Type: news
Celebrex May Not Pose More Heart Risk Than Others
Researchers found more complications, such as bleeding, for the pain relievers ibuprofen and naproxen (Source: WebMD Health)
Source: WebMD Health - November 14, 2016 Category: Consumer Health News Source Type: news
